Annual Operating Expenses
$20.90 M
+$6.48 M+44.96%
31 December 2023
Summary:
Oragenics annual total operating expenses is currently $20.90 million, with the most recent change of +$6.48 million (+44.96%) on 31 December 2023. During the last 3 years, it has risen by +$5.13 million (+32.54%). OGEN annual operating expenses is now -21.54% below its all-time high of $26.64 million, reached on 31 December 2020.OGEN Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$2.44 M
+$131.30 K+5.69%
30 September 2024
Summary:
Oragenics quarterly total operating expenses is currently $2.44 million, with the most recent change of +$131.30 thousand (+5.69%) on 30 September 2024. Over the past year, it has dropped by -$10.36 million (-80.95%). OGEN quarterly operating expenses is now -80.95% below its all-time high of $12.80 million, reached on 31 December 2023.OGEN Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OGEN Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -81.0% |
| 3 y3 years | +32.5% | +5.9% |
| 5 y5 years | +31.6% | -33.4% |
OGEN Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +45.0% | -81.0% | +16.4% |
| 5 y | 5 years | -21.5% | +45.0% | -81.0% | +16.4% |
| alltime | all time | -21.5% | +1153.3% | -81.0% | +377.3% |
Oragenics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.44 M(+5.7%) |
| June 2024 | - | $2.31 M(-6.3%) |
| Mar 2024 | - | $2.46 M(-80.8%) |
| Dec 2023 | $20.90 M(+45.0%) | $12.80 M(+511.0%) |
| Sept 2023 | - | $2.09 M(-32.6%) |
| June 2023 | - | $3.11 M(+7.0%) |
| Mar 2023 | - | $2.90 M(+26.3%) |
| Dec 2022 | $14.42 M(-8.6%) | $2.30 M(-41.1%) |
| Sept 2022 | - | $3.91 M(+8.4%) |
| June 2022 | - | $3.60 M(-21.8%) |
| Mar 2022 | - | $4.61 M(+100.3%) |
| Dec 2021 | $15.77 M(-40.8%) | $2.30 M(-47.6%) |
| Sept 2021 | - | $4.39 M(+14.5%) |
| June 2021 | - | $3.84 M(-26.7%) |
| Mar 2021 | - | $5.24 M(+15.1%) |
| Dec 2020 | $26.64 M(+67.8%) | $4.55 M(+0.9%) |
| Sept 2020 | - | $4.51 M(-63.5%) |
| June 2020 | - | $12.35 M(+136.1%) |
| Mar 2020 | - | $5.23 M(+43.0%) |
| Dec 2019 | $15.88 M(+58.9%) | $3.66 M(-6.7%) |
| Sept 2019 | - | $3.92 M(-20.1%) |
| June 2019 | - | $4.91 M(+44.5%) |
| Mar 2019 | - | $3.39 M(+20.2%) |
| Dec 2018 | $10.00 M(+48.7%) | $2.82 M(+2.2%) |
| Sept 2018 | - | $2.76 M(+21.1%) |
| June 2018 | - | $2.28 M(+7.6%) |
| Mar 2018 | - | $2.12 M(+50.2%) |
| Dec 2017 | $6.72 M(-21.3%) | $1.41 M(-26.5%) |
| Sept 2017 | - | $1.92 M(+37.5%) |
| June 2017 | - | $1.40 M(-29.7%) |
| Mar 2017 | - | $1.99 M(-26.5%) |
| Dec 2016 | $8.54 M(-27.5%) | $2.70 M(+33.4%) |
| Sept 2016 | - | $2.03 M(+16.9%) |
| June 2016 | - | $1.73 M(-16.4%) |
| Mar 2016 | - | $2.08 M(-5.5%) |
| Dec 2015 | $11.78 M(+84.5%) | $2.20 M(+17.7%) |
| Sept 2015 | - | $1.87 M(-70.6%) |
| June 2015 | - | $6.34 M(+325.2%) |
| Mar 2015 | - | $1.49 M(+9.7%) |
| Dec 2014 | $6.39 M(-62.2%) | $1.36 M(+17.0%) |
| Sept 2014 | - | $1.16 M(-44.1%) |
| June 2014 | - | $2.08 M(+16.6%) |
| Mar 2014 | - | $1.78 M(-48.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | $16.90 M(+31.1%) | $3.43 M(-63.8%) |
| Sept 2013 | - | $9.47 M(+339.0%) |
| June 2013 | - | $2.16 M(+16.6%) |
| Mar 2013 | - | $1.85 M(-8.2%) |
| Dec 2012 | $12.89 M(+59.5%) | $2.01 M(-8.3%) |
| Sept 2012 | - | $2.20 M(-68.7%) |
| June 2012 | - | $7.01 M(+322.2%) |
| Mar 2012 | - | $1.66 M(-19.2%) |
| Dec 2011 | $8.08 M(-2.7%) | $2.06 M(+6.7%) |
| Sept 2011 | - | $1.93 M(-17.1%) |
| June 2011 | - | $2.32 M(+31.2%) |
| Mar 2011 | - | $1.77 M(-17.1%) |
| Dec 2010 | $8.30 M(+22.9%) | $2.13 M(+2.2%) |
| Sept 2010 | - | $2.09 M(-4.5%) |
| June 2010 | - | $2.19 M(+15.6%) |
| Mar 2010 | - | $1.89 M(+29.5%) |
| Dec 2009 | $6.75 M(+7.7%) | $1.46 M(-8.4%) |
| Sept 2009 | - | $1.59 M(-0.7%) |
| June 2009 | - | $1.61 M(-23.3%) |
| Mar 2009 | - | $2.09 M(-29.7%) |
| Dec 2008 | $6.27 M(+153.5%) | $2.98 M(+137.5%) |
| Sept 2008 | - | $1.25 M(+12.7%) |
| June 2008 | - | $1.11 M(+20.0%) |
| Mar 2008 | - | $926.10 K(+28.9%) |
| Dec 2007 | $2.47 M(-18.4%) | $718.20 K(+32.4%) |
| Sept 2007 | - | $542.30 K(-13.0%) |
| June 2007 | - | $623.00 K(+6.7%) |
| Mar 2007 | - | $584.10 K(-19.6%) |
| Dec 2006 | $3.03 M(-7.2%) | $726.90 K(+14.6%) |
| Sept 2006 | - | $634.10 K(-20.9%) |
| June 2006 | - | $801.80 K(-7.3%) |
| Mar 2006 | - | $865.10 K(+13.8%) |
| Dec 2005 | $3.26 M(-1.7%) | $760.00 K(+1.3%) |
| Sept 2005 | - | $750.00 K(-14.3%) |
| June 2005 | - | $875.00 K(-199.5%) |
| Mar 2005 | - | -$879.10 K(-167.2%) |
| Dec 2004 | $3.32 M(+99.1%) | $1.31 M(+75.4%) |
| Sept 2004 | - | $745.60 K(+3.1%) |
| June 2004 | - | $723.20 K(-232.8%) |
| Mar 2004 | - | -$544.50 K(-186.5%) |
| Dec 2003 | $1.67 M | $629.20 K(+57.9%) |
| Sept 2003 | - | $398.40 K(-7.9%) |
| June 2003 | - | $432.40 K(+108.0%) |
| Mar 2003 | - | $207.90 K |
FAQ
- What is Oragenics annual total operating expenses?
- What is the all time high annual operating expenses for Oragenics?
- What is Oragenics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Oragenics?
- What is Oragenics quarterly operating expenses year-on-year change?
What is Oragenics annual total operating expenses?
The current annual operating expenses of OGEN is $20.90 M
What is the all time high annual operating expenses for Oragenics?
Oragenics all-time high annual total operating expenses is $26.64 M
What is Oragenics quarterly total operating expenses?
The current quarterly operating expenses of OGEN is $2.44 M
What is the all time high quarterly operating expenses for Oragenics?
Oragenics all-time high quarterly total operating expenses is $12.80 M
What is Oragenics quarterly operating expenses year-on-year change?
Over the past year, OGEN quarterly total operating expenses has changed by -$10.36 M (-80.95%)